Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma.

A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

EEDVD-682 is under clinical development by EnGeneIC and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) ...

Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 30% phase transition ...

DF-003 is under clinical development by Drug Farm and currently in Phase I for Unspecified Ophthalmological Disorders.